On November 16, Kodiak Sciences Inc. fell 4.09% in Regular Trading, trading at $103.14 per share, with turnover of $22.8831 million.
The move appears tied to continued market digestion of the company’s latest quarterly results, which showed a wider third-quarter loss, higher research and development spending, and ongoing cash-consumption concerns.
Kodiak Sciences Inc. reported third-quarter EPS of $(1.05), missing the $(1.01) consensus estimate, while net loss widened 8% year over year to $66.22 million. Research and development expense rose 16% to $58.30 million, driven mainly by increased clinical and manufacturing activity. Although the company said multi-indication regulatory submissions for Zenkuda remain planned for the fourth quarter and at least one firm raised its price target to $150, near-term trading focus has stayed on the earnings miss and cost pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)